Translational Bridge & TME CRO Service Discount Program

PharmaPlanter maintains a strategic synergy with the University of British Columbia (UBC), serving as a vital bridge between academic excellence and industrial application. We offer a collaborative ecosystem where high-precision engineering meets groundbreaking research to solve complex biological challenges.

Focus: Advancing Research through High-Fidelity Therapeutic Modelling and Experimental Validation.


This program provides UBC researchers and physician-scientists with discounted access to our specialized TME (Therapeutic Modelling and Experimentation) platform. We specialize in developing the most physiologically relevant research models and conducting rigorous experimental studies to bridge the gap between in vitro concepts and in vivo clinical potential.

UBC Researcher Priority Access

Benefit Type Details Eligibility
1. Project Discount 15% OFF total project cost Any project initiated by you or your students/team
2. Fast-Track Launch Project kicks off within 3 business days after approval, with priority lab and staff All UBC-affiliated projects
3. Free Project Scoping 1 hour of complimentary project design or technical consultation with our scientists Available during early-stage planning for new projects
4. Referral Rewards Earn 5% service credit if your referral signs a project; the referred researcher receives 10% off Open to all researchers sharing leads or collaborators
5. Flexible Payment Split payments by milestone or phase for projects over $10,000 to ease budget Applies to qualifying larger projects

Workday System Access - UBC Guide

UBC Investigators can find us directly through the Workday platform. We are listed under approved service providers. For quick reference:

  • “PharmaPlanter Technologies Inc.”

  • SUP-110412

  • Research Services

  • For step-by-step instructions on how to find and engage with us through the UBC Workday platform, Click here to view the visual guide.

What We’ve Accomplished & Support

Preclinical and Translational Research Support

  • Validated syngeneic and xenograft cancer models (e.g., tumor growth, biomarker response)

  • Developed custom immune challenge models to assess pathway modulation

  • Performed cell line validation, sourcing, and authentication for clean reproducibility

  • Carried out cytokine and chemokine profiling to support immunological hypotheses

  • Provided in vivo pharmacokinetics/toxicology studies in early exploratory formats

  • Designed and executed oral FMT (Fecal Microbiota Therapy) Phase 2 studies

Assay, Protocol & AUP Development Support

  • Co-developed and optimized custom assays and workflows in collaboration with academic labs - including immune readouts, molecular biology protocols, and dosing regimens.

  • Assisted researchers in designing and refining Animal Use Protocols (AUPs) to align with ethical standards and experimental goals including pilot planning and technical details for ACC submission.

  • Provided feedback on experimental feasibility, dosing schedules, and expected variability to help labs avoid costly design missteps.

  • Integrated both in vitro and in vivo workflows to support mechanism-based studies with seamless data flow across platforms.

  • Helped optimize SOPs for scalability or reproducibility

  • Offered trial-and-error flexibility for early-phase testing and iteration

Full Platform Support

  • Full-Platform Synergy: Partners can leverage the integrated power of all six core technology platforms including Neoantigen AI, iPSC-Organoids, and our proprietary Gas Vesicle (GV) technology to ensure seamless data continuity from molecule design to biological validation.

    Custom Model Development: We design disease-specific 3D architectures and specialized biological models tailored to your specific therapeutic hypotheses.

Collaborative Scientific Input

  • Delivered technical consultations during scoping phase at no cost

  • Provided model selection advice based on disease relevance, timeline, and cost

  • Offered alternatives for limited-resource setups (e.g., shared controls, staggered runs)

  • Helped new faculty get preclinical data rapidly to support lab launch

  • Provided access to animal and wet lab infrastructure without setup burden

What Researchers Say About Us

  • "I like the progress so far... Thank you all very much. Very clear."

    Director of Business Development, UBC Spin-off Company

  • "Thanks for the clarity on the use of the cell lines. Your group has been great to work with."

    Chief Executive Officer, University of Alberta Spin-off Company

  • "The report looks good - very comprehensive and clear. Happy to see the nice cytokine results."

    Director of Operations, UBC Spin-off Company

  • "Thnx all for your attention… This is very clear and OK w me."

    Principle Investigator at Department of Medicine, UBC